GENE ONLINE|News &
Opinion
Blog

Lokavant Secures $8 Million Investment from Mitsui to Expand Clinical Trial Intelligence Across Asia-Pacific

by Sinead Huang
Share To

Clinical trial intelligence platform company Lokavant has secured an $8 million strategic investment from the global business giant Mitsui & Co. Ltd. The investment is aimed at expanding Lokavant’s AI-optimized platform throughout the Asia-Pacific (APAC) region. Lokavant, an innovative player in the clinical research field, will utilize Mitsui’s support to open a new APAC headquarters in Tokyo.

Related article: Revolutionary Technology Aims to Detect and Prevent Dementia and Mental Illness

Mitsui Backs Lokavant’s Trailblazing Clinical Trial Intelligence

Mitsui’s investment in Lokavant follows a year-long collaboration between the two companies, which involved extensive due diligence by Mitsui in assessing the global clinical trials landscape. 

Mitsui was encouraged by Lokavant’s cutting-edge clinical trial intelligence technology and its successful track record in Japan, where it serves customers such as CMIC Group, the largest contract research organization (CRO) in Japan. The investment also entails operational support, encompassing business development, staffing, and product localization, with a primary focus on Japan. The new regional headquarters of Mitsui in Tokyo will serve as a hub for customer support and operations across APAC.

With this Series A extension, Mitsui joins previous investors, including Edison Partners and Roivant Sciences. In total, Lokavant has raised $29 million in funding, enabling the company to expand its intelligence technology for various applications. These applications range from trial participant diversity modeling to site feasibility planning. Notably, Lokavant recently launched its Study Planning solution and initiated a collaboration with a top-10 pharmaceutical customer.

Leveraging Data for Enhanced Clinical Trials

Lokavant leverages a proprietary data asset comprising historical trial data from over 2,000 studies, involving more than 14,000 investigators and 12,000 healthcare institutions. This wealth of data is integrated with real-world data (RWD) sources. Lokavant’s platform and analytical applications empower pharmaceutical companies to enhance the accuracy and efficiency of trial planning and execution. Their Clinical Trial Intelligence Platform provides sponsors and CROs with real-time, predictive analytics in a continuous feedback loop, leading to a remarkable 70x improvement in enrollment forecast accuracy, over $1 million in cost savings attributed to patient retention, and a time savings of six months for detecting site noncompliance issues.

Rohit Nambisan, CEO, and co-founder of Lokavant expressed the significance of the company’s platform and its expansion into the Asia-Pacific region. He noted, “Lokavant’s platform has driven significant value to pharmaceutical sponsors and CROs on global clinical trials, and with exceptional validation of the platform in Japan, it is a natural next step to launch Lokavant Asia. With a distinguished track record in international business and a rapidly growing reputation in life sciences innovation, Mitsui is the ideal strategic partner for the creation of Lokavant AsiaPac.”

This strategic partnership between Lokavant and Mitsui marks a significant development in the field of clinical trials, promising advanced solutions and greater efficiency in drug development and healthcare research across the APAC region.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
R&D
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
LATEST
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
EVENT
Scroll to Top